Your browser doesn't support javascript.
loading
Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast.
Ciniselli, Chiara M; Verderio, Paolo; Baili, Paolo; Sant, Milena; Pizzamiglio, Sara; Duroni, Valeria; de Braud, Filippo G; Folli, Secondo; Scaperrotta, Gianfranco; De Santis, Maria C; Apolone, Giovanni; De Marco, Cinzia; Vingiani, Andrea; Cappelletti, Vera; Pruneri, Giancarlo; Di Cosimo, Serena.
Afiliación
  • Ciniselli CM; Department of Epidemiology and Data Science, Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Verderio P; Department of Epidemiology and Data Science, Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: paolo.verderio@istitutotumori.mi.it.
  • Baili P; Department of Epidemiology and Data Science, Data Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sant M; Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pizzamiglio S; Department of Epidemiology and Data Science, Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Duroni V; Department of Epidemiology and Data Science, Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • de Braud FG; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Milan, Milano, Italy.
  • Folli S; Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Scaperrotta G; Breast Imaging Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Santis MC; Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Apolone G; Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Marco C; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vingiani A; University of Milan, Milano, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cappelletti V; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pruneri G; University of Milan, Milano, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Di Cosimo S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Clin Breast Cancer ; 2024 Aug 08.
Article en En | MEDLINE | ID: mdl-39209598
ABSTRACT

BACKGROUND:

Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer, with 5-10% of cases progressing into invasive disease. Herein, we investigated the association between HER2-low and clinico-pathological characteristics in DCIS and subsequent ipsilateral loco-regional relapse (LRR). MATERIALS AND

METHODS:

We accessed our prospectively maintained institutional database. HER2 status was determined by immunohistochemistry and classified as null (score 0), over-expressed (3+), and low (1+ or 2+); in situ hybridization was not considered since it is not used for routine DCIS diagnostics.

RESULTS:

Among 375 patients with DCIS, median age was 54 (27-88) years, with a primary tumor size < 2.5 cm in 63%, grade III in 33%, and positive hormone receptor status (HR) in 81% of cases; 71% underwent breast-conserving surgery, 34% received adjuvant endocrine and 39% radiotherapy. A total of 197 (52%) had tumors with low HER2 expression, which resulted significantly associated with grade I/II (P < .001), Ki67< 20% (P < .001), and HR-positive status (P < .001). HER2-low distribution varied from 19.61% and 50% in ER negative and ER-low (<10%) to 60% and 69% in ER high (50%-95%) and very high tumors (> 95%) (P < .001). After a median 39-month follow-up (IQR 16-65), cumulative incidences of LRR was 0.054. Among 17 patients with paired primary tumor and LRR, 5 had discordant HER2 status, with an even distribution of increased and decreased HER2 expression.

CONCLUSIONS:

Low HER2 expression in DCIS is associated with features of reduced aggressiveness. Importantly, changes in HER2 expression may occur prompting retesting in recurrent cases, in line with observations in invasive breast cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos